How is Halotestin taken?
| Strength | Tablet colour | Bottle sizes |
|---|---|---|
| 2 mg1 | Peach | 100 |
| 5 mg1 | Light green | 100 |
| 10 mg1 | Green | 30 and 100 |
The Halotestin label gives a daily dose of 5 to 20 mg by mouth for complete replacement in the hypogonadal male, which it says will suffice in the majority of patients, taken singly or in three or four divided doses, from 2 mg, 5 mg and 10 mg tablets.1
Tablet strengths and route
The table is set at the top of the page
The label describes Halotestin only as a tablet for oral administration, with no mixing or syringe step.1 Among the sources found, buccal use appears only in Capponi 1985, a bioavailability study in which six subjects each took 10-mg fluoxymesterone tablets buccally and orally in a crossover.2
What the label gives for dose and schedule
For complete replacement in the hypogonadal male, the label gives 5 to 20 mg a day for most patients.1 The total daily oral dose may be given once or in three or four divided doses, and it varies with the individual, the condition and its severity.1 The label says priapism is indicative of excessive dosage and is indication for temporary withdrawal of the drug, and that liver function tests are to be obtained periodically because of the hepatotoxicity associated with 17-alpha-alkylated androgens.1
For delayed puberty in males, the label says to titrate from a low dose, monitor the skeleton and limit therapy to four to six months.1 The label gives no milligram dose or numeric steps for delayed puberty beyond titrating from a low dose.1
For palliative therapy of advanced inoperable breast cancer in women, the label gives 10 to 40 mg a day in total.1 Because of its short action, the label says fluoxymesterone is to be given in divided, rather than single, daily doses to ensure more stable blood levels.1
What trials gave
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Ingle 20063 | Fluoxymesterone 10 mg orally twice a day for 1 year added to tamoxifen 20 mg a day for 5 years, against tamoxifen alone | 541 eligible postmenopausal women with resected ER-positive early breast cancer | 1 year of fluoxymesterone; median follow-up 11.4 years |
| Ingle 1988 and 1991 update45 | Fluoxymesterone 10 mg orally twice daily plus tamoxifen 10 mg orally twice daily, against tamoxifen alone; patients failing tamoxifen could later receive fluoxymesterone | 119 postmenopausal women with metastatic breast cancer per arm | Not stated |
| Tormey 19836 | Fluoxymesterone given orally twice a day at 7 mg/m2 body surface area, with tamoxifen given orally twice a day at 2 to 100 mg/m2, against tamoxifen alone | 108 women with metastatic breast cancer, 56 on the combination and 52 on tamoxifen alone | Not stated |
| Strickland 19937 | 2.5 mg oral fluoxymesterone daily | Eighty-two short boys (71 with constitutional delay of growth and puberty, 11 with genetic short stature), with 34 untreated boys followed | 6 to 60 months |
| Loprinzi 19998 | Fluoxymesterone 10 mg orally twice a day, against dexamethasone 0. 75 mg four times a day or megestrol acetate 800 mg orally every day | People with cancer anorexia or cachexia (number not stated) | Not stated |
| Brubaker 19829 | 30 mg/day oral fluoxymesterone plus necessary transfusions, against transfusions alone | Previously untreated patients with anaemia (haemoglobin 10 g/dL or less): 16 with myelofibrosis and 13 with other myeloproliferative disorders; 24 could be evaluated | Not stated |
| French Cooperative Group 198610 | Fluoxymesterone or norethandrolone at 1 mg/kg/d or 0.2 mg/kg/d; four androgens at high doses in a second comparison | 110 patients with aplastic anaemia, and 125 others in the four-androgen comparison | Not stated |
Strickland concluded that a daily oral dose of 2.5 mg of fluoxymesterone can be used to accelerate linear growth in boys with constitutional delay of growth and puberty and genetic short stature when needed to alleviate emotional problems secondary to slow growth and short stature, without fear of compromising final adult height.7 Loprinzi found fluoxymesterone resulted in significantly less appetite enhancement and did not have a favorable toxicity profile.8 The French Cooperative Group concluded that androgen therapy is truly efficient in moderately severe aplastic anaemia and that fluoxymesterone (1 mg/kg/d) for 18 months is to be chosen as the reference drug for any new androgen therapy assay.10
How Halotestin tablets are stored
The label says to store tablets at controlled room temperature of 20° to 25°C (68° to 77°F).1
Frequently asked questions
Is Halotestin a controlled substance?
The label says fluoxymesterone is a controlled substance under the Anabolic Steroids Control Act and that Halotestin tablets have been assigned to Schedule III.1
Is fluoxymesterone prohibited in sport?
The WADA Prohibited List names fluoxymesterone among the S1.1 anabolic androgenic steroids, in the S1 anabolic agents class it lists as prohibited at all times, in and out of competition.11
Is Halotestin still marketed?
Current marketing status was not established from the sources searched.
Is there dosing information beyond the label?
Beyond the label, the sources found are the trials in the table above and Capponi 1985, a six-subject bioavailability study; searches of DailyMed, ClinicalTrials.gov and PubMed found no newer label, no stability data and no dose trial in healthy people.2
References
- Pharmacia and Upjohn Company (DailyMed). Halotestin ® CIII fluoxymesterone tablets, USP. 2006. dailymed.nlm.nih.gov
- PubMed. Liquid chromatographic assay for fluoxymesterone in human serum with application to a preliminary bioavailability study. 1985. pubmed.ncbi.nlm.nih.gov
- PubMed. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. 2006. pubmed.ncbi.nlm.nih.gov
- PubMed. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. 1988. pubmed.ncbi.nlm.nih.gov
- PubMed. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. 1991. pubmed.ncbi.nlm.nih.gov
- PubMed. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. 1983. pubmed.ncbi.nlm.nih.gov
- PubMed. Long-term results of treatment with low-dose fluoxymesterone in constitutional delay of growth and puberty and in genetic short stature. 1993. pubmed.ncbi.nlm.nih.gov
- PubMed. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. 1999. pubmed.ncbi.nlm.nih.gov
- PubMed. Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. 1982. pubmed.ncbi.nlm.nih.gov
- PubMed. Androgen therapy in aplastic anaemia: a comparative study of high and low-doses and of 4 different androgens. French Cooperative Group for the Study of Aplastic and Refractory Anemias. 1986. pubmed.ncbi.nlm.nih.gov
- WADA. WORLD ANTI-DOPING CODE. wada-ama.org